The role of Arg445 and Asp498 in the human thyroid hormone transporter MCT8

Endocrinology

Volumn 155, Issue 2, 2014, Pages 618-626

  Groeneweg, Stefan ^a   Friesema, Edith C H ^a   Kersseboom, Simone ^a   Klootwijk, Wim ^a   Visser, W Edward ^a   Peeters, Robin P ^a   Visser, Theo J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ASPARTIC ACID; COMPLEMENTARY DNA; MONOCARBOXYLATE TRANSPORTER 8; THYROXINE;

ARTICLE; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DIMERIZATION; GENE MUTATION; GENETIC TRANSFECTION; HORMONE TRANSPORT; HUMAN; HUMAN CELL; METABOLIC CAPACITY; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN STRUCTURE; THYROID HORMONE METABOLISM; WESTERN BLOTTING; WILD TYPE;

BIOLOGICAL TRANSPORT; CELL LINE; HUMANS; MONOCARBOXYLIC ACID TRANSPORTERS; MUTAGENESIS, SITE-DIRECTED; MUTATION; THYROID GLAND; THYROID HORMONES;

EID: 84893175242     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1521     Document Type: Article

References (34)

1. Bianco AC, Kim BW. Deiodinases: implications of the local control of thyroid hormone action. J Clin Invest. 2006;116: 2571-2579.
2. Yen PM, Ando S, Feng X, Liu Y, Maruvada P, Xia X. Thyroid hormone action at the cellular, genomic and target gene levels. Mol Cell Endocrinol. 2006;246: 121-127.
3. Hennemann G, Docter R, Friesema EC, de Jong M, Krenning EP, Visser TJ. Plasma membrane transport of thyroid hormones and its role in thyroid hormone metabolism and bioavailability. Endocr Rev. 2001;22: 451-476.
4. Friesema EC, Ganguly S, Abdalla A, et al. Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter. J Biol Chem. 2003;278: 40128-40135.
5. Friesema EC, Grueters A, Biebermann H, et al. Association between mutations in a thyroid hormone transporter and severe X-linked psychomotor retardation. Lancet. 2004;364: 1435-1437.
6. Dumitrescu AM, Liao XH, Best TB, Brockmann K, Refetoff S. A novel syndrome combining thyroid and neurological abnormalities is associated with mutations in a monocarboxylate transporter gene. Am J Hum Genet. 2004;74: 168-175.
7. Friesema EC, Visser WE, Visser TJ. Genetics and phenomics of thyroid hormone transport by MCT8. Mol Cell Endocrinol. 2010;322: 107-113.
8. Jansen J, Friesema EC, Kester MH, Schwartz CE, Visser TJ. Genotype- phenotype relationship in patients with mutations in thyroid hormone transporter MCT8. Endocrinology. 2008;149: 2184-2190.
9. Kinne A, Kleinau G, Hoefig C, et al. Essential molecular determinants for thyroid hormone transport and first structural implications for monocarboxylate transporter 8. J Biol Chem. 2010;285: 28054-28063.
10. Vaurs-Barrière C, Deville M, Sarret C, et al. Pelizaeus- Merzbacherlike disease presentation ofMCT8mutated male subjects. Ann Neurol. 2009;65: 114-118.
11. Ugrasbul F, Ardinger HH. A patient presenting with central hypothyroidism, developmental delay and poor head control. Should we be checking T3 levels? Horm Res. 2009;72(suppl 3): 458-459.
12. Braun D, Lelios I, Krause G, Schweizer U. Histidines in potential substrate recognition sites affect thyroid hormone transport by monocarboxylate transporter 8 (MCT8). Endocrinology 2013;154: 2553-2561.
13. Groeneweg S, Lima de Souza EC, Visser WE, Peeters RP, Visser TJ. Importance of His192 in the human thyroid hormone transporter MCT8 for substrate recognition. Endocrinology. 2013;154: 2525-2532.
14. Mol JA, Visser TJ. Synthesis and some properties of sulfate esters and sulfamates of iodothyronines. Endocrinology. 1985;117: 1-7.
15. Friesema EC, Kuiper GG, Jansen J, Visser TJ, Kester MH. Thyroid hormone transport by the human monocarboxylate transporter 8 and its rate-limiting role in intracellular metabolism. Mol Endocrinol. 2006;20: 2761-2772.
16. Friesema EC, Jansen J, Jachtenberg JW, Visser WE, Kester MH, Visser TJ. Effective cellular uptake and efflux of thyroid hormone by human monocarboxylate transporter 10. Mol Endocrinol. 2008; 22: 1357-1369.
17. Wilson MC, Meredith D, Bunnun C, Sessions RB, Halestrap AP. Studies on the DIDS-binding site of monocarboxylate transporter 1 suggest a homology model of the open conformation and a plausible translocation cycle. J Biol Chem. 2009;284: 20011-20021.
18. Rahman B, Schneider HP, Bröer A, Deitmer JW, Bröer S. Helix 8 and helix 10 are involved in substrate recognition in the rat monocarboxylate transporter MCT1. Biochemistry. 1999;38: 11577-11584.
19. Manoharan C, Wilson MC, Sessions RB, Halestrap AP. The role of charged residues in the transmembrane helices of monocarboxylate transporter 1 and its ancillary protein basigin in determining plasma membrane expression and catalytic activity. MolMembrBiol. 2006; 23: 486-498.
20. Law CJ, Almqvist J, Bernstein A, et al. Salt-bridge dynamics control substrate-induced conformational change in the membrane transporter GlpT. J Mol Biol. 2008;378: 828-839.
21. Smits G, Govaerts C, Nubourgh I, Pardo L, Vassart G, Costagliola S. Lysine 183 and glutamic acid 157 of the TSH receptor: two interacting residues with a key role in determining specificity toward TSH and human CG. Mol Endocrinol. 2002;16: 722-735.
22. Dumitrescu AM, Liao XH, Weiss RE, Millen K, Refetoff S. Tissuespecific thyroid hormone deprivation and excess in monocarboxylate transporter (mct) 8-deficient mice. Endocrinology. 2006;147: 4036-4043.
23. Trajkovic M, Visser TJ, Mittag J, et al. Abnormal thyroid hormone metabolism in mice lacking the monocarboxylate transporter 8. J Clin Invest. 2007;117: 627-635.
24. Wirth EK, Sheu SY, Chiu-Ugalde J, et al. Monocarboxylate transporter 8 deficiency: altered thyroid morphology and persistent high triiodothyronine/ thyroxine ratio after thyroidectomy. Eur J Endocrinol. 2011;165: 555-561.
25. Wirth EK, Roth S, Blechschmidt C, et al. Neuronal 3',3,5-triiodothyronine (T3) uptake and behavioral phenotype of mice deficient in Mct8, the neuronal T3 transporter mutated in Allan-Herndon-Dudley syndrome. J Neurosci. 2009;29: 9439-9449.
26. Mayerl S, Visser TJ, Darras VM, Horn S, Heuer H. Impact of oatp1c1 deficiency on thyroid hormone metabolism and action in the mouse brain. Endocrinology. 2012;153: 1528-1537.
27. Lima de Souza EC, Groeneweg S, Visser WE, Peeters RP, Visser TJ. Importance of cysteine residues in the thyroid hormone transporter MCT8. Endocrinology. 2013;154: 1948-1955.
28. Kirk P, Wilson MC, Heddle C, Brown MH, Barclay AN, Halestrap AP.CD147is tightly associated with lactate transportersMCT1and MCT4 and facilitates their cell surface expression. EMBO J. 2000; 19: 3896-3904.
29. Philp NJ, Ochrietor JD, Rudoy C, Muramatsu T, Linser PJ. Loss of MCT1, MCT3, and MCT4 expression in the retinal pigment epithelium and neural retina of the 5A11/basigin-null mouse. Invest Ophthalmol Vis Sci. 2003;44: 1305-1311.
30. Wilson MC, Meredith D, Fox JE, Manoharan C, Davies AJ, Halestrap AP. Basigin (CD147) is the target for organomercurial inhibition of monocarboxylate transporter isoforms 1 and 4: the ancillary protein for the insensitive MCT2 is Embigin (gp70). J Biol Chem. 2005;280: 27213-27221.
31. VisserEW,Philp NJ,VanDijk TB, et al. Evidence for a homodimeric structure ofhumanmonocarboxylate transporter 8. Endocrinology. 2009;150: 5163-5170.
32. Lewis HA, Zhao X, Wang C, et al. Impact of the ΔF508 mutation in first nucleotide-binding domain of human cystic fibrosis transmembrane conductance regulator on domain folding and structure. J Biol Chem 2005;280:1346-1353.
33. Sharma M, Pampinella F, Nemes C, et al. Misfolding diverts CFTR from recycling to degradation: quality control at early endosomes. J Cell Biol. 2004;164: 923-933.
34. Moyer BD, Denton J, Karlson KH, et al. A PDZ-interacting domain in CFTR is an apical membrane polarization signal. J Clin Invest. 1999;104: 1353-1361.